SEC Form 4 · accession 0001840599-26-000003

BlossomHill Therapeutics, Inc. · BLSM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 6, 2026

Accepted (ET)

Aug 10, 2026 · 6:29 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001839970

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Aug 10, 2026	C	578,524	—	A	578,524	I	By Brahma BlossomHill Partners, LLC

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Director Stock Option (Right to Buy)^F3	$16.00	Aug 6, 2026	A	23,904	A	—	Aug 5, 2036	Common Stock	23,904	23,904	D
Series B Preferred Stock^F1,F2	—	Aug 10, 2026	C	578,524	D	—	—	Common Stock	578,524	0	I

F1Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F31/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.